Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)

British Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2002, Pages 463-471

  Van Kesteren, Charlotte ^a   Mathot R A A ^a   Raymond, E ^b   Armand, J P ^b   Fumoleau, P ^c   Punt, C ^d   Ravic, M ^e   Wanders, J ^f   Beijnen, J H ^a,g   Schellens, J H M ^a,g,h  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e EISAI CO LTD   (Japan)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

D optimality; E7070; Limited sampling; Pharmacokinetics; Population pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; INDISULAM; UNCLASSIFIED DRUG;

ACCURACY; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BAYES THEOREM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SAMPLING STUDIES; SULFONAMIDES;

EID: 18744416827     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01684.x     Document Type: Article

References (22)

1. Owa T, Okachi T, Yoshimatsu K, et al. A focused compound library of novel N-(7-indolyl) benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg Med Chem Lett 2000;10: 1223-1226.
2. Owa T, Yoshino H, Okauchi T, et al. Discovery of novel anti-tumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 1999;42: 3789-3799.
3. Fukuoka K, Usuda J, Fukumoto H, et al. Mechanism of action of a novel sulfonamide antitumor agent, E7070. Proc Am Assoc Cancer Res 2000;41: 59.
4. Raymond E, ten Bokkel Huinink WW, Taied J. Phase I and pharmacokinetic study of E7070, a new chloro-indolysulfonamide, given as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Proc Am Assoc Cancer Res 2000;41: 611.
5. Punt CJA, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with advanced solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG). Ann Oncol 2001;12: 1289-1293.
6. Droz JP, Roch H, Zanetta S, et al. Phase I trial of five-days continuous infusion E7070 [N (3-chloro-7-indoly) -1,4-bezene-disulfonamide] in patients with solid tumors. Proc Am Assoc Cancer Res 2001;41: 609.
7. Dittrich C, Dumez H, Calvert H. Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single IV infusion, weekly x 4, q 6 weeks. Proc Am Assoc Cancer Res 2001;41: 609.
8. Raymond E, Fumoleau P, Roché H, et al. Combined results of 4 phase I and pharmacokinetic studies of E7070, a novel chloroindoly-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clin Cancer Res 2000;6: 4529s.
9. Jodrell DI, Murray LS, Hawtof J, Graham MA, Egorin MJ. A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemother Pharmacol 1996;37: 356-362.
10. Sørensen BT, Stömgren A, Jakobsen P, Jakobsen A. A limited sampling method for the estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993;31: 324-327.
11. Van Warmerdam LJC, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Limited sampling models for anticancer agents. J Cancer Res Clin Oncol 1994;120: 427-433.
12. Baille P, Bruno R, Schellens JHM, et al. Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 1997;3: 1535-1538.
13. Thomson AH, Whitting B Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22: 447-467.
14. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981;9: 739-756.
15. Beal SL, Boeckman AJ, Sheiner LB. NONMEM. User's Guide, Part V. San Francisco: University of California at San Francisco, 1988.
16. van Kesteren Ch, Mathôt RAA, Raymond E, et al. Population pharmacokinetic analysis of the novel anti-cancer agent E7070 in three phase I clinical studies using non-linear mixed effects modeling (NONMEM). Proc Am Soc Clin Oncol 2001;20: 93a.
17. Karlsson MO, Molnar V, Freijs A, et al. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999;27: 1220-1223.
18. D'Argenio DZ, Schumitzky A. ADAPT II Users Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software, Biomedical Simulations Resource. Los Angeles: University of Southern California, 1997.
19. Kerbusch T, De Kraker J, Mathôt RAA, Beijnen JH. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: A sparse sampling approach. Clin Pharmacokinet 2001;40: 615-625.
20. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9: 503-512.
21. van den Bongard HJGD, Mathôt RAA, Beijnen JH, et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000;39: 345-367.
22. Merlé Y, Mentré F, Mallet A. Designing an optimal experiment for Bayesian estimation: Application to the kinetics of iodine thyroid uptake. Stat Med 1994;13: 185-196.